04.24.15
The Denver-based Colorado BioScience Association (CBSA) has appointed Mark Spiecker as its new chairman of the board of directors. Spiecker, the CEO of Sharklet Technologies and outgoing CBSA vice chairman of the board, will lead CBSA for a two-year term. He was appointed along with eight new board members and nine returning board members during the CBSA annual board retreat on April 22.
Spiecker replaces outgoing chair Derek Cole, the president of investor relations advisory solutions, who will continue to serve on the CBSA board and executive committee through 2016.
Spiecker leads Sharklet Technologies Inc., which develops surface technologies designed to address microorganism growth and make healthier, safer and cleaner environments.
“Colorado’s bioscience sector continues to flourish thanks to the dynamic business environment in Colorado and the comprehensive services and support offered by the Colorado Bioscience Association. Along with my fellow board members, I’m proud to serve an organization that contributes to the success and vitality of our bioscience community,” Spieckler said.
Also joining the CBSA board leadership positions are:
• Vice Chairman: Scott Larson, Senior Vice President, Legal, and General Counsel, Terumo BCT
• Treasurer: Jim Wilson, Partner, E&Y
• Secretary: Lisa Drake, Director of Government Affairs, Monsanto
Newly appointed board members include:
• Ginny Orndorff, Director, CID4
• Kate Tallman, Associate Vice President, University of Colorado Technology Transfer Office
• Alan Rudolph, Ph.D., Vice President for Research, Colorado State University
• Gary Connell, Co-President, Sheridan Ross
• Lauren Costantini, Ph.D., CEO, Prima-Temp
• Milo Metcalf, Vice President of Operations, Allosource
• Fintan Steele, Ph.D., Executive Director of Communications, SomaLogic
• Larry Blankenship, Evergreen Research
“We look forward to additional growth under Mark and the executive team’s stewardship, and we thank Derek Cole for his leadership and our outgoing board members for their extraordinary commitments of time and talent to support CBSA and our state’s bioscience industry,” said April Giles, president and CEO of CBSA.
Re-appointed board members include:
• Lisa Drake, Director of Government Affairs, Monsanto
• Brent Fassett, Partner, Cooley
• Kiki Traylor, M.D., Director of State Government Affairs, Amgen
• Dan Wittenberg, Partner, Snell & Willmer LLP
• Mark Lupa, Ph.D., Partner, High Country Venture
• Dick Hinson, Senior Vice President, Aurora Economic Development Council
• James Chomas, Ph.D., Founder & CEO, Surefire Medical
• Steve VanNurden, President & CEO, Fitzsimons Redevelopment Authority
Industry leaders from the state’s biotechnology, medical device, diagnostic, pharmaceutical, healthcare and research sectors, as well as businesses that provide critical products and services to bioscience companies make up the board of directors.
Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 600 bioscience companies.
Spiecker replaces outgoing chair Derek Cole, the president of investor relations advisory solutions, who will continue to serve on the CBSA board and executive committee through 2016.
Spiecker leads Sharklet Technologies Inc., which develops surface technologies designed to address microorganism growth and make healthier, safer and cleaner environments.
“Colorado’s bioscience sector continues to flourish thanks to the dynamic business environment in Colorado and the comprehensive services and support offered by the Colorado Bioscience Association. Along with my fellow board members, I’m proud to serve an organization that contributes to the success and vitality of our bioscience community,” Spieckler said.
Also joining the CBSA board leadership positions are:
• Vice Chairman: Scott Larson, Senior Vice President, Legal, and General Counsel, Terumo BCT
• Treasurer: Jim Wilson, Partner, E&Y
• Secretary: Lisa Drake, Director of Government Affairs, Monsanto
Newly appointed board members include:
• Ginny Orndorff, Director, CID4
• Kate Tallman, Associate Vice President, University of Colorado Technology Transfer Office
• Alan Rudolph, Ph.D., Vice President for Research, Colorado State University
• Gary Connell, Co-President, Sheridan Ross
• Lauren Costantini, Ph.D., CEO, Prima-Temp
• Milo Metcalf, Vice President of Operations, Allosource
• Fintan Steele, Ph.D., Executive Director of Communications, SomaLogic
• Larry Blankenship, Evergreen Research
“We look forward to additional growth under Mark and the executive team’s stewardship, and we thank Derek Cole for his leadership and our outgoing board members for their extraordinary commitments of time and talent to support CBSA and our state’s bioscience industry,” said April Giles, president and CEO of CBSA.
Re-appointed board members include:
• Lisa Drake, Director of Government Affairs, Monsanto
• Brent Fassett, Partner, Cooley
• Kiki Traylor, M.D., Director of State Government Affairs, Amgen
• Dan Wittenberg, Partner, Snell & Willmer LLP
• Mark Lupa, Ph.D., Partner, High Country Venture
• Dick Hinson, Senior Vice President, Aurora Economic Development Council
• James Chomas, Ph.D., Founder & CEO, Surefire Medical
• Steve VanNurden, President & CEO, Fitzsimons Redevelopment Authority
Industry leaders from the state’s biotechnology, medical device, diagnostic, pharmaceutical, healthcare and research sectors, as well as businesses that provide critical products and services to bioscience companies make up the board of directors.
Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 600 bioscience companies.